MA33854B1 - Protéines de liaison à antigène humain qui se lient à bêta-klotho, aux récepteurs de fgf et aux complexes de ceux-ci - Google Patents
Protéines de liaison à antigène humain qui se lient à bêta-klotho, aux récepteurs de fgf et aux complexes de ceux-ciInfo
- Publication number
- MA33854B1 MA33854B1 MA35017A MA35017A MA33854B1 MA 33854 B1 MA33854 B1 MA 33854B1 MA 35017 A MA35017 A MA 35017A MA 35017 A MA35017 A MA 35017A MA 33854 B1 MA33854 B1 MA 33854B1
- Authority
- MA
- Morocco
- Prior art keywords
- binding proteins
- antigen
- klotho
- fgfric
- fgfr3c
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Radiology & Medical Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
Abstract
La présente invention porte sur des compositions et des procédés se rapportant à des protéines de liaison à un antigène qui activent la signalisation à médiation par fgf21 ou provenant de celles-ci. Dans des modes de réalisation, les protéines de liaison à un antigène se lient de façon spécifique (i) à ²-klotho; (ii) à fgfric, fgfr2c, fgfr3c ou fgfr4; ou (iii) à un complexe comportant ²-klotho et à l'un parmi fgfric, fgfr2c, fgfr3c, et fgfr4. Dans certains modes de réalisation, les protéines de liaison à un antigène induisent une signalisation de type fgf21. Dans certains modes de réalisation, les protéines de liaison à un antigène sont des anticorps complètement humains, humanisés ou chimériques, des fragments de liaison et des dérivés de tels anticorps, et des polypeptides qui se lient de façon spécifique (i) à ²-klotho; (ii) à fgfric, fgfr2c, fgfr3c ou fgfr4; ou (iii) à un complexe comprenant ²-klotho et à l'un parmi fgfric, fgfr2c, fgfr3c et fgfr4. D'autres modes de réalisation concernent des acides nucléiques codant pour de telles protéines de liaison à un antigène, fragments et dérivés de celles-ci et polypeptides, des cellules comportant de tels poly-nucléotides, des procédés de fabrication de telles protéines de liaison à un antigène, fragments et dérivés de celles-ci et polypeptides, et des procédés d'utilisation de telles protéines de liaison à un antigène, fragments et dérivés de celles-ci et polypeptides, comprenant des procédés de traitement ou de diagnostic de sujets souffrant de diabète de type 2, d'obésité, de stéatose hépatique non alcoolique, du syndrome métabolique et de troubles ou états s'y rapportant.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26732109P | 2009-12-07 | 2009-12-07 | |
US38184610P | 2010-09-10 | 2010-09-10 | |
PCT/US2010/058984 WO2011071783A1 (fr) | 2009-12-07 | 2010-12-03 | Protéines de liaison à antigène humain qui se lient à bêta-klotho, aux récepteurs de fgf et aux complexes de ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33854B1 true MA33854B1 (fr) | 2012-12-03 |
Family
ID=43545013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35017A MA33854B1 (fr) | 2009-12-07 | 2012-06-28 | Protéines de liaison à antigène humain qui se lient à bêta-klotho, aux récepteurs de fgf et aux complexes de ceux-ci |
Country Status (36)
Country | Link |
---|---|
US (4) | US9284378B2 (fr) |
EP (4) | EP2711375B1 (fr) |
JP (4) | JP5840619B2 (fr) |
KR (3) | KR102121678B1 (fr) |
CN (2) | CN108586602A (fr) |
AR (1) | AR079274A1 (fr) |
AU (1) | AU2010328444B2 (fr) |
BR (1) | BR112012013876B1 (fr) |
CA (2) | CA2782420C (fr) |
CL (1) | CL2012001504A1 (fr) |
CR (2) | CR20180020A (fr) |
CY (1) | CY1119000T1 (fr) |
DK (1) | DK2711375T3 (fr) |
EA (2) | EA026129B1 (fr) |
ES (2) | ES2633810T3 (fr) |
HR (1) | HRP20170882T1 (fr) |
HU (1) | HUE034727T2 (fr) |
IL (2) | IL220048A0 (fr) |
LT (1) | LT2711375T (fr) |
MA (1) | MA33854B1 (fr) |
ME (1) | ME02807B (fr) |
MX (2) | MX360487B (fr) |
MY (2) | MY173097A (fr) |
NZ (2) | NZ717847A (fr) |
PE (1) | PE20121686A1 (fr) |
PL (1) | PL2711375T3 (fr) |
PT (1) | PT2711375T (fr) |
RS (1) | RS56016B1 (fr) |
SG (2) | SG10201708609PA (fr) |
SI (1) | SI2711375T1 (fr) |
TN (1) | TN2012000268A1 (fr) |
TW (3) | TWI693234B (fr) |
UA (1) | UA109888C2 (fr) |
UY (2) | UY33089A (fr) |
WO (1) | WO2011071783A1 (fr) |
ZA (1) | ZA201204145B (fr) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002051438A2 (fr) | 2000-12-22 | 2002-07-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Utilisation de rgm et de ses modulateurs |
WO2002077546A1 (fr) * | 2001-03-14 | 2002-10-03 | Sekisui Chemical Co., Ltd. | Pompe de chaleur, et systeme de pompe de chaleur |
EP1928905B1 (fr) | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Domaines de liaison de proteines de la famille proteinique des molecules de guidage repulsif (rgm), fragments fonctionnels de ces domaines et leur utilisation |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
BR112012013734A2 (pt) * | 2009-12-08 | 2017-01-10 | Abbott Gmbh & Co Kg | anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina. |
EP2707718A1 (fr) * | 2011-05-10 | 2014-03-19 | Amgen Inc. | Procédé d'identification de composés qui modulent spécifiquement l'interaction de fgfr1 et de bêta-klotho |
CN103596980B (zh) | 2011-05-16 | 2017-08-08 | 霍夫曼-拉罗奇有限公司 | Fgfr1激动剂及使用方法 |
US9574002B2 (en) * | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
KR102077721B1 (ko) | 2011-07-01 | 2020-02-14 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법 |
AU2012301769B2 (en) | 2011-08-31 | 2016-05-19 | Amgen Inc. | FGF21 for use in treating type 1 diabetes |
CN104220460A (zh) * | 2011-12-08 | 2014-12-17 | 安姆根有限公司 | 激动人lcat抗原结合蛋白和它们在疗法中的用途 |
IL297229A (en) | 2012-01-27 | 2022-12-01 | Abbvie Inc | The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells |
AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
WO2014085365A2 (fr) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions et méthodes de traitement de troubles et maladies métaboliques |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
CN108888757A (zh) | 2012-12-27 | 2018-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法 |
TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
NZ711376A (en) | 2013-03-15 | 2020-01-31 | Sanofi Sa | Heteroaryl compounds and uses thereof |
JP6668241B2 (ja) | 2013-09-05 | 2020-03-18 | アムジエン・インコーポレーテツド | 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すFc含有分子 |
WO2015065897A1 (fr) | 2013-10-28 | 2015-05-07 | Ngm Biopharmaceuticals, Inc. | Modèles de cancer et procédés associés |
US9644023B2 (en) | 2013-12-09 | 2017-05-09 | New York University | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
RU2701434C2 (ru) | 2014-01-24 | 2019-09-26 | Нгм Биофармасьютикалс, Инк. | Связывающие белки и способы их применения |
JP6712230B2 (ja) | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
WO2015148708A1 (fr) * | 2014-03-25 | 2015-10-01 | Regeneron Pharmaceuticals, Inc. | Agonistes du récepteur fgf21 et leurs utilisations |
JP6671298B2 (ja) | 2014-05-16 | 2020-03-25 | アムジェン インコーポレイテッド | Th1及びth2細胞集団を検出するためのアッセイ |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
WO2015195509A2 (fr) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire |
EP3209681A4 (fr) | 2014-10-23 | 2018-10-31 | NGM Biopharmaceuticals, Inc. | Compositions pharmaceutiques comprenant des variants de peptide et leurs procédés d'utilisation |
WO2016073855A1 (fr) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires |
WO2017019957A2 (fr) * | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Protéines de liaison et leurs procédés d'utilisation |
CN108350072B (zh) * | 2015-08-03 | 2022-05-24 | 诺华股份有限公司 | 治疗fgf21相关病症的方法 |
CA2997290A1 (fr) * | 2015-09-24 | 2017-03-30 | Genentech, Inc. | Methodes pour le traitement de l'epilepsie |
CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
EP3371217A1 (fr) | 2015-11-08 | 2018-09-12 | H. Hoffnabb-La Roche Ag | Procédés de criblage d'anticorps multispécifiques |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
CN107177002B (zh) * | 2016-03-09 | 2021-02-09 | 郑州鸿运华宁生物医药有限公司 | 一种能与人β-Klotho受体特异性结合的抗体及其用途 |
MY196095A (en) * | 2016-03-23 | 2023-03-14 | Seoul Nat Univ R&Db Foundation | Antibody That Binds to Envelope Glycoprotein of Severe Fever With Thrombocytopenia Syndrome Virus and use for Same |
CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
EP3502143A4 (fr) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | Peptide de liaison pour la construction d'une protéine de fusion |
CN106317226B (zh) | 2016-08-19 | 2017-09-05 | 安源医药科技(上海)有限公司 | 用于构建融合蛋白的连接肽 |
WO2018039557A1 (fr) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19 |
AU2018218557B9 (en) | 2017-02-08 | 2021-06-24 | Novartis Ag | FGF21 mimetic antibodies and uses thereof |
CA3056011A1 (fr) | 2017-03-14 | 2018-09-20 | Amgen Inc. | Controle des glycoformes afucosylees totales d'anticorps produits en culture cellulaire |
WO2018226750A1 (fr) * | 2017-06-06 | 2018-12-13 | Relinia, Inc. | Protéines de fusion agonistes du récepteur 2 du tnf monocaténaire |
US11365228B2 (en) | 2017-07-06 | 2022-06-21 | Yale University | Mutant FGF21 polypeptide compositions |
KR101917854B1 (ko) * | 2017-08-24 | 2018-11-12 | 한국콜마주식회사 | 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물 |
US20210079065A1 (en) | 2018-03-26 | 2021-03-18 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
US11932681B2 (en) * | 2018-05-31 | 2024-03-19 | Novartis Ag | Hepatitis B antibodies |
CN112239507A (zh) * | 2019-07-17 | 2021-01-19 | 鸿运华宁(杭州)生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用 |
WO2021062372A1 (fr) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Procédés de production de compositions d'anticorps |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
EP4162257A1 (fr) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique |
US20220010021A1 (en) | 2020-07-02 | 2022-01-13 | Sanofi | FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides |
CA3197930A1 (fr) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Glycanes relatifs non apparies dans des procedes de production d'anticorps |
EP4255487A1 (fr) * | 2020-12-04 | 2023-10-11 | The University of Chicago | Polypeptides de détection et de traitement d'infection à coronavirus |
JP2024517844A (ja) | 2021-05-04 | 2024-04-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性fgf21受容体アゴニスト及びそれらの使用 |
CA3222409A1 (fr) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Utilisation de fucosidase pour controler le taux d'afucosylation de proteines glycosylees |
WO2023046071A1 (fr) * | 2021-09-23 | 2023-03-30 | 江苏恒瑞医药股份有限公司 | Anticorps anti-klb et leurs utilisations |
WO2023059607A1 (fr) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Liaison de récepteur fc-gamma et teneur en glycane |
WO2023125745A1 (fr) * | 2021-12-30 | 2023-07-06 | 上海津曼特生物科技有限公司 | ANTICORPS ANTI-βKLOTHO ET SON UTILISATION |
WO2023215725A1 (fr) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions et méthodes pour l'immunothérapie cellulaire |
Family Cites Families (205)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
EP0088046B1 (fr) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipides en phase aqueuse |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (fr) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Composition pharmaceutique contenant de l'urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0154316B1 (fr) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Lymphokine chimiquement modifiée et son procédé de préparation |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
CA1310924C (fr) | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Systeme d'administration d'un medicament a l'aide de particules infectieuses |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US4970154A (en) | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5288855A (en) | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
JP3039802B2 (ja) | 1989-07-06 | 2000-05-08 | ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア | 繊維芽細胞成長因子のための受容体 |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
EP0779362B2 (fr) | 1989-12-22 | 2012-06-13 | Laboratoires Serono SA | Constructions de type ADN pour l'activation et la modification de l'expression de gènes endogènes |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
WO1991010470A1 (fr) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Dispositifs et procedes d'apport ameliore de facteurs actifs |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5672510A (en) | 1990-01-19 | 1997-09-30 | Genetic Therapy, Inc. | Retroviral vectors |
AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
EP1403285A1 (fr) | 1990-07-06 | 2004-03-31 | Gencell S.A. | Récepteurs de facteur de croissance fibroblastique |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (fr) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Animaux non humains transgeniques capables de produire des anticorps heterologues |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5217889A (en) | 1990-10-19 | 1993-06-08 | Roninson Igor B | Methods and applications for efficient genetic suppressor elements |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5229501A (en) | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
CA2105984C (fr) | 1991-03-11 | 2002-11-26 | Milton J. Cormier | Clonage et expression de la luciferase de renilla |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
JPH06508035A (ja) | 1991-06-14 | 1994-09-14 | ディーエヌエックス コーポレーション | トランスジェニックブタにおけるヒトヘモグロビンの生産 |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
EP0593592B1 (fr) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Copolymere en masse segmentee a cristaux liquides thermotropiques |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
IL100219A0 (en) | 1991-12-02 | 1992-09-06 | Yeda Res & Dev | Variable region within fibroblast growth factor receptors that confers ligand specificity |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
WO1993015722A1 (fr) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Liberation controlee de produits pharmaceutiques a partir de microparticules poreuses preformees |
US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
US5364791A (en) | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
DK0672141T3 (da) | 1992-10-23 | 2003-06-10 | Immunex Corp | Fremgangsmåder til fremstilling af opløselige, oligomere proteiner |
US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
JPH08509870A (ja) | 1993-05-26 | 1996-10-22 | オンタリオ キャンサー インスティテュート | 特定のcd45イソ型タンパク質の発現を遮断するトランスジェニック哺乳動物 |
US6664107B1 (en) | 1993-05-26 | 2003-12-16 | Ontario Cancer Institute, University Health Network | CD45 disrupted nucleic acid |
DE705334T1 (de) | 1993-06-14 | 1999-12-30 | Basf Ag | Strenge kontrolle der genexpression in eukaryotischen zellen durch auf tetrazyklin ansprechende promotoren |
US5589362A (en) | 1993-06-14 | 1996-12-31 | Basf Aktiengesellschaft | Tetracycline regulated transcriptional modulators with altered DNA binding specificities |
US5654168A (en) | 1994-07-01 | 1997-08-05 | Basf Aktiengesellschaft | Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
EP1179350A3 (fr) | 1993-08-12 | 2003-01-02 | Cytotherapeutics, Inc. | Système cellulaire encapsulé pour implantation dans le SNC hunain |
WO1995007463A1 (fr) | 1993-09-10 | 1995-03-16 | The Trustees Of Columbia University In The City Of New York | Methodes d'utilisation de proteines fluorescentes vertes |
WO1995021191A1 (fr) | 1994-02-04 | 1995-08-10 | William Ward | Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
EP1978033A3 (fr) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Anticorps humains dérivés à partir de xénosouris immunisée |
JPH11506319A (ja) | 1995-05-26 | 1999-06-08 | ゼネカ・リミテッド | エクジソンレセプターを含む遺伝子スイッチ |
WO1996041865A1 (fr) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Regulation d'evenements biologiques fondee sur la rapamycine |
EP0832269A1 (fr) | 1995-06-07 | 1998-04-01 | Baylor College Of Medicine | Transporteurs d'acide nucleique servant a introduire des acides nucleiques dans une cellule |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
ATE465149T1 (de) | 1996-02-28 | 2010-05-15 | Ariad Pharma Inc | Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen |
WO1997034631A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
US6214795B1 (en) | 1996-11-12 | 2001-04-10 | Praecis Pharmaceuticals, Inc. | Peptide compounds useful for modulating FGF receptor activity |
CA2616914C (fr) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Anticorps de liaison de recepteur d'egf |
AU741076B2 (en) | 1996-12-12 | 2001-11-22 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
CN1167795C (zh) | 1996-12-26 | 2004-09-22 | 协和发酵工业株式会社 | 肽、dna及抗体 |
CA2196496A1 (fr) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
DE69839571D1 (de) | 1997-11-25 | 2008-07-10 | Genentech Inc | Fibroblasten-wachstumsfaktor-19 |
US6150098A (en) | 1998-02-20 | 2000-11-21 | Amgen Inc. | Methods for identifying novel secreted mammalian polypeptides |
EP1064360B1 (fr) | 1998-03-27 | 2008-03-05 | Prolume, Ltd. | Luciferases, proteines fluorescentes gfp, leurs acides nucleiques, et leur utilisation en diagnostic |
US6101683A (en) * | 1998-04-02 | 2000-08-15 | Avery Dennison Corporation | Loop fastener, fastener clip including same and loop fastener dispensing tool |
CA2341029A1 (fr) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Production de molecules modifiees avec demi-vie serique prolongee |
US6548634B1 (en) | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000027885A1 (fr) | 1998-11-05 | 2000-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau popypeptide chimerique |
US6656728B1 (en) | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
JP2002539176A (ja) | 1999-03-15 | 2002-11-19 | カイロン コーポレイション | 眼の疾患を処置または予防するための組換え遺伝子送達ベクターの使用 |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
GB9916482D0 (en) | 1999-07-15 | 1999-09-15 | British Aerospace | Terrain navigation apparatus for a legged animal traversing terrain |
CA2311201A1 (fr) | 1999-08-05 | 2001-02-05 | Genset S.A. | Sequences marqueurs exprimees et proteines humaines codees |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US7408047B1 (en) | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
AU7368100A (en) | 1999-09-10 | 2001-04-10 | Curagen Corporation | Fibroblast growth factor polypeptide and nucleic acids encoding same |
WO2001032678A1 (fr) | 1999-11-05 | 2001-05-10 | Smithkline Beecham Corporation | sbgFGF-19a |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
AU1922101A (en) | 1999-11-18 | 2001-05-30 | Chiron Corporation | Human fgf-21 gene and gene expression products |
AU1628101A (en) | 1999-11-22 | 2001-06-04 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
US7108984B2 (en) | 2000-01-12 | 2006-09-19 | Mount Sinai School Of Medicine | Methods of identifying modulators of the FGF receptor |
WO2001049849A1 (fr) | 2000-01-05 | 2001-07-12 | Zymogenetics, Inc. | Zfgf11 : nouvel homologue de fgf |
US20020081663A1 (en) | 2000-01-05 | 2002-06-27 | Conklin Darrell C. | Novel FGF homolog ZFGF11 |
US20020001825A1 (en) | 2000-03-31 | 2002-01-03 | Nobuyuki Itoh | Fibroblast growth factor-like molecules and uses thereof |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
IL139380A0 (en) | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20040018499A1 (en) | 2001-06-06 | 2004-01-29 | Lal Preeti G | Extracellular messengers |
JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
MXPA04000231A (es) | 2001-07-11 | 2004-05-04 | Maxygen Holdings Ltd | Conjugados del factor de estimulacion de colonias de granulocitos. |
US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
US20050187150A1 (en) | 2001-10-31 | 2005-08-25 | New York University | Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds |
AU2003201810A1 (en) | 2002-01-15 | 2003-07-30 | Eli Lilly And Company | Method for reducing morbidity and mortality in critically ill patients |
EP1332761A1 (fr) | 2002-01-31 | 2003-08-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Agonistes des récepteurs du facteur de croissance des fibroblastes |
CN100531796C (zh) | 2002-01-31 | 2009-08-26 | 马普科技促进协会 | Fgfr激动剂 |
CN1162704C (zh) * | 2002-06-17 | 2004-08-18 | 北京大学 | 一种检测人血液中Klotho蛋白的方法 |
AU2003265057A1 (en) | 2002-09-04 | 2004-03-29 | Abtech | Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy |
AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
JP2006515747A (ja) | 2002-11-01 | 2006-06-08 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
JP2007524566A (ja) | 2002-12-20 | 2007-08-30 | エンカム ファーマシューティカルズ アクティーゼルスカブ | レセプターとリガンドの間の相互作用の調節の方法 |
TWI300430B (en) * | 2003-01-10 | 2008-09-01 | Ritek Corp | Optical recording medium dye and optical recording medium using thereof |
WO2004083381A2 (fr) | 2003-03-13 | 2004-09-30 | Indiana University Advanced Research & Technology Institute | Polynucleotides, polypeptides et mutants des recepteurs 1 du facteur de croissance des fibroblastes |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
JP2006240990A (ja) | 2003-05-15 | 2006-09-14 | Kirin Brewery Co Ltd | klothoタンパク質および抗klothoタンパク質抗体ならびにそれらの用途 |
AU2004251145C1 (en) | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
SI1641483T1 (sl) | 2003-06-12 | 2008-08-31 | Lilly Co Eli | Fuzijski proteini |
PT1680140E (pt) * | 2003-10-16 | 2011-05-31 | Imclone Llc | Inibidores do receptor-1 do factor de crescimento de fibroblastos e m?todos de tratamento destes |
JP4477013B2 (ja) | 2003-12-10 | 2010-06-09 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子21の突然変異タンパク質 |
US20070248605A1 (en) | 2003-12-19 | 2007-10-25 | Five Prime Therapetutics, Inc. | Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention |
WO2005072769A1 (fr) | 2004-01-26 | 2005-08-11 | Eli Lilly And Company | Utilisation du fgf-21 et d'une thiazolidinedione dans le traitement du diabete de type 2 |
WO2005091944A2 (fr) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Composes fgf-21 lies au glycol |
DE602005016917D1 (de) | 2004-05-13 | 2009-11-12 | Lilly Co Eli | Fgf-21-fusionsproteine |
WO2006028714A1 (fr) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteines du facteur de croissance 21 du fibroblaste |
PT1789442E (pt) | 2004-09-02 | 2009-11-11 | Lilly Co Eli | Muteínas do factor de crescimento de fibroblasto 21 |
EP1814573B1 (fr) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf) |
US7655627B2 (en) * | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
WO2006078463A2 (fr) | 2005-01-21 | 2006-07-27 | Eli Lilly And Company | Methode de traitement de maladie cardio-vasculaire |
JP2006246823A (ja) | 2005-03-11 | 2006-09-21 | Kyoto Univ | 造血因子としてのFgf21の使用 |
WO2006130527A2 (fr) | 2005-05-31 | 2006-12-07 | Novartis Ag | Mutations et polymorphismes de recepteur du facteur de croissance 1 des fibroblastes |
NZ565511A (en) | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
ZA200800970B (en) | 2005-08-15 | 2009-10-28 | Genentech Inc | Gene disruptions, compositions and methods relating thereto |
US8043833B2 (en) | 2005-10-31 | 2011-10-25 | Novo Nordisk A/S | Expression of soluble therapeutic proteins |
EP1996216A2 (fr) | 2006-02-28 | 2008-12-03 | Trustees Of Boston University | Procedes d'identification de facteurs associes a la croissance musculaire et leurs utilisations |
EP2046384A4 (fr) | 2006-06-15 | 2009-12-02 | Fibron Ltd | Anticorps bloquant l'activation du récepteur du facteur de croissance des fibroblastes et leurs procédés d'utilisation |
CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
WO2008057683A2 (fr) | 2006-10-03 | 2008-05-15 | Novo Nordisk A/S | Méthodes de purification de conjugués de polypeptides |
KR20140012199A (ko) | 2007-03-30 | 2014-01-29 | 암브룩스, 인코포레이티드 | 변형된 fgf-21 폴리펩티드 및 그 용도 |
CA2682096A1 (fr) | 2007-04-02 | 2009-01-15 | Genentech, Inc. | Klotho beta |
JP5187837B2 (ja) * | 2007-04-06 | 2013-04-24 | 独立行政法人産業技術総合研究所 | 補助因子による受容体の活性化方法並びにリガンド活性の利用方法 |
US7537903B2 (en) | 2007-04-23 | 2009-05-26 | Board Of Regents, The University Of Texas System | FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner |
KR20100017169A (ko) | 2007-05-22 | 2010-02-16 | 노파르티스 아게 | Fgf21-관련 장애의 치료, 진단 및 검출 방법 |
WO2008149521A1 (fr) | 2007-05-29 | 2008-12-11 | Immuno-Biological Labolatories Co., Ltd | Agent thérapeutique contre le cancer et procédé de traitement du cancer |
JP2010531135A (ja) | 2007-06-04 | 2010-09-24 | ノボ ノルディスク アクティーゼルスカブ | N−アセチルグルコサミニルトランスフェラーゼを使用したo結合型グリコシル化 |
EP2185178B1 (fr) | 2007-08-03 | 2017-08-23 | Eli Lilly And Company | Utilisation d'un composé du fgf-21 et d'un composé du glp-1 pour le traitement de l'obésité |
EP2497783A3 (fr) | 2007-09-26 | 2013-04-17 | U3 Pharma GmbH | Protéines de liaison avec l'antigène du facteur de croissance de type facteur de croissance épidermique se liant à l'héparine |
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
WO2010006214A1 (fr) | 2008-07-09 | 2010-01-14 | Ambrx, Inc. | Anticorps de neutralisation de fgf-21 et leurs utilisations |
CA2732449A1 (fr) | 2008-08-04 | 2010-02-11 | Five Prime Therapeutics, Inc. | Muteines de region acide de domaine extracellulaire de fgfr |
JP2012502649A (ja) | 2008-09-19 | 2012-02-02 | メディミューン,エルエルシー | Cd105を対象とする標的結合剤およびその使用 |
DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
DK3248610T3 (da) | 2009-05-05 | 2024-01-15 | Amgen Inc | Fgf21-mutanter og anvendelser deraf |
AU2010326024A1 (en) * | 2009-12-02 | 2012-07-05 | Amgen Inc. | Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho |
UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
US9401875B2 (en) | 2012-06-01 | 2016-07-26 | Nippon Telegraph And Telephone Corporation | Packet transfer processing method and packet transfer processing device |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2010
- 2010-03-12 UA UAA201208326A patent/UA109888C2/ru unknown
- 2010-12-03 US US12/960,407 patent/US9284378B2/en active Active
- 2010-12-03 ME MEP-2017-108A patent/ME02807B/fr unknown
- 2010-12-03 SG SG10201708609PA patent/SG10201708609PA/en unknown
- 2010-12-03 EP EP13183846.8A patent/EP2711375B1/fr active Active
- 2010-12-03 CR CR20180020A patent/CR20180020A/es unknown
- 2010-12-03 AU AU2010328444A patent/AU2010328444B2/en active Active
- 2010-12-03 LT LTEP13183846.8T patent/LT2711375T/lt unknown
- 2010-12-03 KR KR1020187015615A patent/KR102121678B1/ko active IP Right Grant
- 2010-12-03 CN CN201711402977.6A patent/CN108586602A/zh active Pending
- 2010-12-03 EA EA201270634A patent/EA026129B1/ru unknown
- 2010-12-03 NZ NZ717847A patent/NZ717847A/en unknown
- 2010-12-03 EP EP16207166.6A patent/EP3202787B1/fr active Active
- 2010-12-03 KR KR1020127017717A patent/KR101865974B1/ko active IP Right Grant
- 2010-12-03 BR BR112012013876-6A patent/BR112012013876B1/pt active IP Right Grant
- 2010-12-03 DK DK13183846.8T patent/DK2711375T3/en active
- 2010-12-03 NZ NZ700473A patent/NZ700473A/en unknown
- 2010-12-03 MX MX2016010041A patent/MX360487B/es unknown
- 2010-12-03 HU HUE13183846A patent/HUE034727T2/en unknown
- 2010-12-03 ES ES10788204.5T patent/ES2633810T3/es active Active
- 2010-12-03 EP EP20178046.7A patent/EP3760642A1/fr active Pending
- 2010-12-03 SI SI201031477A patent/SI2711375T1/sl unknown
- 2010-12-03 CN CN201080063309.5A patent/CN102858802B/zh active Active
- 2010-12-03 EP EP10788204.5A patent/EP2510009B1/fr active Active
- 2010-12-03 PE PE2012000781A patent/PE20121686A1/es active IP Right Grant
- 2010-12-03 WO PCT/US2010/058984 patent/WO2011071783A1/fr active Application Filing
- 2010-12-03 PL PL13183846T patent/PL2711375T3/pl unknown
- 2010-12-03 ES ES13183846T patent/ES2631135T3/es active Active
- 2010-12-03 CA CA2782420A patent/CA2782420C/fr active Active
- 2010-12-03 MY MYPI2012002532A patent/MY173097A/en unknown
- 2010-12-03 MX MX2012006467A patent/MX341148B/es active IP Right Grant
- 2010-12-03 EA EA201691176A patent/EA033405B1/ru not_active IP Right Cessation
- 2010-12-03 CA CA2981687A patent/CA2981687C/fr active Active
- 2010-12-03 JP JP2012543173A patent/JP5840619B2/ja active Active
- 2010-12-03 KR KR1020207015902A patent/KR20200067924A/ko not_active Application Discontinuation
- 2010-12-03 RS RS20170486A patent/RS56016B1/sr unknown
- 2010-12-03 MY MYPI2016000186A patent/MY191950A/en unknown
- 2010-12-03 PT PT131838468T patent/PT2711375T/pt unknown
- 2010-12-03 SG SG2012042008A patent/SG181568A1/en unknown
- 2010-12-06 UY UY0001033089A patent/UY33089A/es not_active Application Discontinuation
- 2010-12-06 AR ARP100104498A patent/AR079274A1/es active IP Right Grant
- 2010-12-06 TW TW106117037A patent/TWI693234B/zh active
- 2010-12-06 TW TW108141373A patent/TW202033554A/zh unknown
- 2010-12-06 TW TW099142419A patent/TWI600761B/zh active
-
2012
- 2012-05-28 TN TNP2012000268A patent/TN2012000268A1/en unknown
- 2012-05-29 IL IL220048A patent/IL220048A0/en active IP Right Grant
- 2012-06-06 ZA ZA2012/04145A patent/ZA201204145B/en unknown
- 2012-06-07 CL CL2012001504A patent/CL2012001504A1/es unknown
- 2012-06-28 MA MA35017A patent/MA33854B1/fr unknown
- 2012-07-06 CR CR20120366A patent/CR20120366A/es unknown
-
2015
- 2015-11-10 JP JP2015220080A patent/JP6240138B2/ja active Active
-
2016
- 2016-02-02 US US15/012,939 patent/US9493577B2/en active Active
- 2016-09-29 US US15/280,662 patent/US10570205B2/en active Active
-
2017
- 2017-04-24 CY CY20171100456T patent/CY1119000T1/el unknown
- 2017-06-08 HR HRP20170882TT patent/HRP20170882T1/hr unknown
- 2017-11-02 JP JP2017212467A patent/JP6931590B2/ja active Active
-
2018
- 2018-09-04 IL IL261585A patent/IL261585B/en unknown
-
2019
- 2019-12-12 JP JP2019224298A patent/JP7065822B2/ja active Active
-
2020
- 2020-01-16 US US16/744,734 patent/US20200216546A1/en active Pending
-
2021
- 2021-03-10 UY UY0001039124A patent/UY39124A/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33854B1 (fr) | Protéines de liaison à antigène humain qui se lient à bêta-klotho, aux récepteurs de fgf et aux complexes de ceux-ci | |
Evenepoel et al. | Parathyroid hormone metabolism and signaling in health and chronic kidney disease | |
Eshkar Sebban et al. | The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation | |
WO2011130417A3 (fr) | Protéines de liaison au récepteur de fgf humain et à β-klotho | |
Haffner et al. | Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study | |
EP3447074A3 (fr) | Protéines de liaison à un antigène humain qui se lient à un complexe comprenant bêta-klotho et un récepteur de fgf | |
EA200701292A1 (ru) | Композиции, содержащие антитела против рецептора igf-1, и способы получения антител | |
Reddy et al. | Association of increased levels of MCP-1 and cathepsin-D in young onset type 2 diabetes patients (T2DM-Y) with severity of diabetic retinopathy | |
GB2414732A (en) | Human antibodies specific for interleukin 15 (IL-15) | |
MX2007008017A (es) | Polipeptidos que se ligan a br3 y usos de los mismos. | |
BRPI0621800B8 (pt) | anticorpos que se ligam à proteína fzd10, clones de hibridoma, composições farmacêuticas, kit compreendendo os referidos anticorpos, e método para diagnose ou prognose de uma doença que é associada a homólogo fzd10 ou de uma predisposição para desenvolver a doença em um indivíduo | |
KR102424496B1 (ko) | 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물 | |
JP2023527609A (ja) | Flt3結合タンパク質および使用方法 | |
WO2006116442A3 (fr) | Anticorps monoclonaux et leurs methodes d'utilisation dans la detection d'une maladie cervicale | |
JP2016520594A (ja) | 強皮症治療のための抗ccl2及び抗loxl2併用療法 | |
Rispens et al. | Hybrid IgG4/IgG4 Fc antibodies form upon ‘Fab-arm’exchange as demonstrated by SDS-PAGE or size-exclusion chromatography | |
WO2006005583A3 (fr) | Especes de polypeptides secretes impliques dans la sclerose en plaques | |
Inoue et al. | Suppression of adiponectin by aberrantly glycosylated IgA1 in glomerular mesangial cells in vitro and in vivo | |
Topaloglu et al. | Clinicopathological and immunohistological features in childhood IgA nephropathy: a single-centre experience | |
Arora et al. | Cryoglobulinemia in a patient with chronic lymphocytic leukemia—a case report and review of literature of renal involvement in CLL | |
AR118006A2 (es) | PROTEÍNAS DE ENLACE A ANTÍGENOS HUMANAS QUE ENLAZAN b-KLOTHO, RECEPTORES FGF Y COMPLEJOS DE LOS MISMOS | |
JO3379B1 (ar) | بروتينات ربط الأنتيجين البشري التي تربط b-klotho ومستقبلات fgf ومجموعاتها | |
Stone et al. | External Validation of a Urinary Biomarker Risk Score for the Prediction of Steroid Responsiveness in Adults With Nephrotic Syndrome | |
EA201991493A2 (ru) | Антиген-связывающие белки человека, которые связываются с -клото, рецепторами fgf и их комплексами | |
TH147119A (th) | โปรตีนที่จับกับแอนติเจนของมนุษย์ที่จับ (เบตา)- Klotho, ตัวรับ FGF และสารเชิงซ้อนของมัน |